Elisa Llurba, Fatima Crispi, Francesca Crovetto, Lina Youssef, Juan Luis Delgado, Isabel Puig, Josefina Mora, Ladislav Krofta, Katerina Mackova, Alicia Martinez-Varea, Albert Tubau, Aina Ruiz, Antoni Paya, Maria Prat, Frederic Chantraine, Carmina Comas, Anna Kajdy, Maria Fernanda Lopez-Tinajero, Francesc Figueras, Eduard Gratacos
INTRODUCTION: Pre-eclampsia affects ~5%-7% of pregnancies. Although improved obstetric care has significantly diminished its associated maternal mortality, it remains a leading cause of maternal morbidity and mortality in the world. Term pre-eclampsia accounts for 70% of all cases and a large proportion of maternal-fetal morbidity related to this condition. Unlike in preterm pre-eclampsia, the prediction and prevention of term pre-eclampsia remain unsolved. Previously proposed approaches are based on combined third-trimester screening and/or prophylactic drugs, but these policies are unlikely to be widely implementable in many world settings...
March 8, 2024: BMJ Open